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Abstract
The synergistic activity between nitric oxide (NO) released from diazeniumdiolate-modified
proline (PROLI/NO) and silver (I) sulfadiazine (AgSD) was evaluated against Escherichia coli,
Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and
Staphylococcus epidermidis using a modified broth microdilution technique and a checkerboard-
type assay. The combination of NO and AgSD was defined as synergistic when the fractional
bactericidal concentration (FBC) was calculated to be <0.5 Gram-negative species were generally
more susceptible to the individual antimicrobial agents than the Gram-positive bacteria. The in
vitro synergistic activity of AgSD and NO observed against a range of pathogens strongly
supports future investigation of this therapeutic combination, particularly for its potential use in
the treatment of chronic and burn wounds.
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Introduction
The antimicrobial properties of silver and more specifically ionic silver (Ag+) have been
recognized and utilized for centuries. Nano- to micromolar concentrations of Ag+ exhibit
broad-spectrum bactericidal, fungicidal, vircidal, and protozoicidal activity,1 bonding
covalently to electron-donating groups (e.g., the sulfhydryl of cysteine) or electrostatically
to negatively-charged molecules (e.g., DNA). Most bacterial sites targeted by Ag+ are
proteinaceous, where alterations in amino acid residues lead to structural damage and
disruption of replicative and metabolic processes, ultimately resulting in cell death.1–6
Evidence suggests that interactions with DNA also play an important role in the
antimicrobial efficacy of Ag+.4, 5 Generally applied as an external treatment, Ag+ is
delivered via silver compounds such as silver (I) sulfadiazine (AgSD).7 Most causative
pathogens related to burns and chronic wound infections are susceptible to the levels of
AgSD attainable topically.8, 9 Fortunately, exposure to clinical levels of Ag+ typically does
not pose a threat to human health, despite the broad range of reactivity.1, 7
Like Ag+, nitric oxide (NO) is a broad-spectrum antimicrobial agent that has a number of
cellular targets and the endogenous expression of NO has been conserved throughout higher
organisms as the immune system’s first-line defense against infection.10–13. Although NO
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can modify proteins and other biological macromolecules directly,14 it is a highly reactive
radical and frequently combines with locally abundant small molecules such as oxygen (O2)
and superoxide (O2−), generating an arsenal of reactive byproducts that include dinitrogen
trioxide (N2O3) and peroxynitrite (ONOO−).10, 15 Collectively these reactive species evoke
potent antibacterial effects by rendering nitrosative and oxidative stresses to bacteria.10, 15–
19 In vitro, NO administered via soluble, small-molecule diazeniumdiolate NO donors, from
nanoparticle delivery vehicles,20–22 and from NO-releasing xerogel coatings.23–25 has been
shown to kill a range of pathogens.
Although the appropriate use of antimicrobials to treat infection is a beneficial practice,
artificial pressures resulting from over use, patient non-compliance, and widespread
application have promoted the unnatural selection of inherently resistant microbes.26 Even
resistance to broad-spectrum agents has been observed.7, 27 To complicate matters, methods
of gene sharing employed by bacteria promote the localized collection of resistance
determinants, often on transferable plasmids, leading to the emergence of multi-drug
resistant (MDR) and extensively drug resistant (XDR) species.28, 29 In recent years, a
dramatic rise in the incidence of ‘super bugs,’ or bacteria that are resistant to those
antibiotics generally reserved as a last resort treatment option (e.g. vancomycin), has been
observed.30, 31 Unfortunately, the discovery of new antimicrobials progresses slowly while
resistance factors to all clinically employed antimicrobial agents emerge rapidly,26 creating
a critical need for alternative approaches to treating infection.
Combination therapy is one strategy for stemming the emergence of resistant species.32–34
The concerted use of two or more biocides with different mechanisms of action decreases
the likelihood that an organism will possess all the traits necessary to ensure its selection and
survival. Agents possessing a broad spectrum of antimicrobial action may both lower the
probability of developing resistance and manage the polymicrobial burden typically found in
topical infections.33, 34 As smaller quantities of each drug are generally required in the
application of combination therapy, dose-related toxicity experienced to a particular biocide
may also be reduced.33, 34 In the best case scenario, the combination of antimicrobials
results in synergistic activity.33, 34 Synergy occurs when two agents working in concert
exert a greater than additive effect, resulting in combinations that are more potent than
equivalent doses administered individually, further reducing potential toxicity to the patient
and cost of treatment. Herein, NO generated from diazeniumdiolate-modified proline
(PROLI/NO) and AgSD were evaluated alone and in combination against 9 pathogenic
microbes using acute (2 h) time-kill viability assays. The synergistic in vitro effect of both
agents was assessed for four Gram-negative and five Gram-positive strains of bacteria,
including two antibiotic-resistant ‘super bugs.’
Materials and methods
Materials
L-proline, sulfadiazine (SD), and AgSD were obtained from Sigma-Aldrich (St. Louis, MO).
Tryptic soy broth (TSB) and tryptic soy agar (TSA) were manufactured by BD (Franklin
Lakes, NJ) and purchased from Fisher Scientific (Pittsburgh, PA). Sodium chloride,
potassium chloride, and sodium phosphate monobasic obtained from Fisher and sodium
phosphate dibasic obtained from Sigma-Aldrich were used to prepare phosphate buffered
saline (PBS, Ic = 0.16 M, pH = 7.4). Distilled water was purified using the Millipore Milli-Q
UV Gradient A-10 system (Bedford, MA) to a resistivity of 18.2 MΩ cm and used to
prepare the reagents for bactericidal assays. Materials used for growing pathogens and/or
evaluating antimicrobial activity were exposed to UV radiation or sanitized in an autoclave
prior to use, unless purchased sterile. Argon, NO, nitrogen (N2), and a NO standard (25.7
ppm in N2) were purchased from National Welders (Raleigh, NC).
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Synthesis and characterization of PROLI/NO
The synthesis protocol reported by Saavedra, et al. was used in the preparation of PROLI/
NO.35 Briefly, 10 g of L-proline was dissolved in 39 mL of 25% sodium methoxide in
methanol. An additional 20 mL of methanol was added, and the solution was placed into a
custom NO reaction bomb, which was then purged with Ar. The proline solution was then
exposed to 5 atm of NO for 3 d to form PROLI/NO as a white precipitate in the methanol.
After purging the bomb with Ar, the precipitate was isolated by vacuum filtration, washed
with ether, and dried under vacuum. The white solid (PROLI/NO) was divided into small
aliquots (< 1 g) and stored over dessicant at −20 °C.
Nitric oxide release from PROLI/NO was characterized using a chemiluminescent NO
analyzer (Sievers Model 280, Boulder, CO). Briefly, a known quantity of PROLI/NO was
inserted into a glass flask containing PBS at 37 °C. Nitric oxide generated into solution via
diazeniumdiolate NO donor decomposition was carried to the analyzer by N2 bubbling
through the solution at a flow rate of 80 mL min−1. The NO analyzer was calibrated using
an atmospheric sample passed through an NO zero filter and a 25.7 ppm NO standard. The
NO release from PROLI/NO was measured periodically to ensure no significant
decomposition of the NO donor over the duration of use.
Bacterial culture
The microbial strains used in this study were obtained from American Type Culture
Collection (ATCC, Manassas, VA). The ATCC identification number for each strain was as
follows: Escherichia coli JM109 (53323), E. coli O157:H7 (35150), vancomycin-susceptible
Enterococcus faecalis (VSEF) (29212), vancomycin-resistant E. faecalis (VREF) (51299),
Proteus mirabilis (29906), Pseudomonas aeruginosa (19143), methicillin-susceptible
Staphylococcus aureus (MSSA) (29213), methicillin-resistant S. aureus (MRSA) (33591),
and Staphylococcus epidermidis (35983). Experiments requiring transfer of biohazardous
materials were conducted in a dedicated laminar flow hood equipped with UV lamp.
Lyophilized bacteria were reconstituted in TSB and cultured overnight at 37 °C. A 1-mL
aliquot of culture was grown in 100 mL of TSB for 2–4 h until reaching an optical density at
600 nm (OD600) ~ 0.15–0.3. The resulting culture was stored at −80 °C in 1-mL aliquots.
For daily experiments, 1 mL of bacteria culture was grown in 100 mL of TSB overnight at
37 °C. Re-cultured in fresh TSB the next day, the bacteria were then grown to mid-
exponential phase, as determined by OD600 measurements (approximately 1 × 108 CFU
mL−1). The relationship between the OD600 and the concentration of bacteria in the culture
suspension was calibrated for each strain using a Spectronic 301 spectrophotometer (Milton
Roy, Ivyland, PA) and enumeration of colony forming units (cfu) from culture dilutions
grown on TSA plates. For single-agent bactericidal assays conducted to determine the
bactericidal activity of PROLI/NO, the 108 cfu mL−1 bacterial suspension was diluted 100-
fold in TSB to obtain a final concentration of 1 × 106 cfu mL−1. For single-agent
bactericidal assays employing AgSD and checkerboard assays, a 50-fold dilution in TSB
was performed, resulting in a 2 × 106 cfu mL−1 bacterial concentration.
Single-agent bactericidal assays
The bactericidal efficacy of single agents (e.g., AgSD, PROLI/NO) after 120 min of
exposure was evaluated against each pathogenic organism using a time-kill protocol. The
minimum bactericidal concentration at 120 min (MBC120) was defined as the concentration
of AgSD or PROLI/NO that resulted in a 3-log reduction in viability for a particular species
over 120 min. Each strain of bacteria was tested in triplicate against 5 concentrations each of
AgSD and PROLI/NO. To determine the efficacy of Ag+, solutions of AgSD in TSB were
prepared and added to an equal volume of 2 × 106 cfu mL−1 bacterial suspension for a final
starting innoculum concentration of 1 × 106 cfu mL−1. To evaluate the efficacy of NO,
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PROLI/NO was pre-weighed into chilled vials, and the appropriate volume of 1 × 106 cfu
mL−1 bacterial suspension was added to obtain the target PROLI/NO concentration.
At each time point (0, 60, and 120 min), a 1:10 dilution of the microbial culture was
prepared in PBS and a 100-μL aliquot of each dilution was spread onto TSA plates and
incubated at 37 °C overnight. The number of colonies was enumerated to evaluate cell
viability at 0, 60, and 120 min.
To circumvent common pitfalls associated with traditional efficacy techniques, some aspects
of the bactericidal assays were modified from standard protocols.36 The most important
features involved obtaining bactericidal (rather than inhibitory) concentrations and requiring
efficacy over acute treatment windows (2 h). The rationale was to ensure swift and efficient
bactericidal efficacy, as these therapeutic parameters discourage the selection of mutated
resistant species. Additionally, we observed the susceptibility of a bacterial strain and its
dose-response to an agent as a function of time by counting viable colonies at 60 and 120
min, rather than simply observing the all-or-none endpoint generated at 24 h by inhibitory
(turbidity) determinations.
Checkerboard assay
The checkerboard method 33 was employed to experimentally determine the efficacy of
AgSD and PROLI/NO in combination. Modifications analogous to those used in the single-
agent bactericidal assays were adopted as described below. Briefly, bacteria (at a final
innoculum concentration of 1 × 106 cfu mL−1) were incubated with an array of antimicrobial
combinations of AgSD and PROLI/NO for 2 h at 37 °C. The highest concentration for each
antimicrobial tested was a two-fold dilution of the concentration determined in the single-
agent assay exhibiting rapid bactericidal activity (≥99%). Three additional dosages at
stepwise, two-fold reductions in concentration were evaluated, resulting in 16 total
combinations of AgSD and PROLI/NO tested against each strain of bacteria. For organisms
that were particularly susceptible to the combination (i.e., MSSA, VSEF, VREF), lower
concentrations of each agent were selected to probe the synergistic limit. Viable cells were
enumerated at 0 and 120 min. The fractional bactericidal concentration index at 120 min
(FBC120) was calculated using Equation 1:
Eq. (1)
adapted from the fractional inhibitory concentration index (FIC) reported by Elion et al., 37
where MBC120A and MBC120B are the values determined for agent A and B, respectively, in
the single-agent assay; and, MBC120AB and MBC120BA are the concentrations of agent A
and B that constituted the most effective bactericidal combination as determined by a 3-log
reduction of viability. Synergy assays were conducted in three independent experiments for
each strain of bacteria. A FBC120 < 0.5 was defined as synergistic, while a FBC120 < 0.25
was considered highly synergistic.
Results
Bactericidal activity of AgSD and PROLI/NO independently
The bactericidal activity of AgSD and PROLI/NO were evaluated against four Gram-
negative (E. coli JM109, E. coli O157:H7, P. aeruginosa and P. mirabilis) and five Gram-
positive (VSEF, VREF, MSSA, MRSA, and S. epidermidis) pathogenic strains of bacteria,
including two antibiotic-resistant varieties. The concentrations required for bactericidal
efficacy for AgSD against the panel of organisms spanned 3 orders of magnitude (Table 1).
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P. aeruginosa exhibited levels of susceptibility in the low micromolar range (56 μM, 0.020
g L−1) comparable to previous reports.4, 38 The bactericidal concentration for E. coli
(0157:H7) was a full order of magnitude greater (560 μM, 0.20 g L−1) than P. aeruginosa,
while MRSA required a ~five-fold greater dose (8960 μM, 3.20 g L−1) than the MSSA
strain. Vancomycin-resistant Enterococcus faecalis required the greatest dose to achieve a 3-
log reduction in viability (11200 μM, 4.0 g L−1).
Bactericidal concentrations of PROLI/NO also varied significantly between pathogens. The
Gram-negative species E. coli (JM109) and P. aeruginosa required the lowest PROLI/NO
doses at 1 g L−1 and 8 g L−1, respectively. The most susceptible Gram-positive strains were
S. epidermidis and MRSA, each requiring 36 g L−1 for 3 logs of bactericidal activity (Table
1). VSEF exhibited the greatest tolerance to NO, withstanding concentrations of PROLI/NO
up to 72 g L−1.
To verify that dissociated SD or regenerated proline did not contribute to observed
cytotoxicity, we examined the bactericidal activity of these compounds with similar testing
protocols. Molar concentrations of SD equivalent to the concentrations required for AgSD
cytotoxicity against S. aureus and P. aeruginosa proved overwhelmingly nontoxic, having
neither a static nor cidal effect. In all cases the bacteria continued to multiply during
treatment, such that populations increased by more than 1 log over 2 h (Figure 1). Proline
exhibited a similar non-toxic effect at concentrations equaling the MBC120 of PROLI/NO
for the two species. Thus, the bactericidal activity of AgSD and PROLI/NO as single agents
can be ascribed to Ag+ and NO, respectively, under the experimental protocol adopted in
this study.
The Gram-positive species studied generally exhibited superior tolerance to the single
agents, Ag+ and NO, when compared to the Gram-negative species. Indeed, the two strains
of E. faecalis indicated the greatest tolerance to both PROLI/NO and AgSD. The resilience
of E. faecalis mirrors a report on the efficacy of dilute honey, another broad-spectrum
antimicrobial, against a variety of bacterial species, where E. faecalis again demonstrated
high levels of antimicrobial tolerance.39 Among the Gram-positive species examined in our
study, the antibiotic-resistant ‘super bugs’ tended to demonstrate greater tolerance to AgSD,
but similar tolerance to NO than their antibiotic-susceptible congeners. We observed that
MRSA exhibited significantly greater tolerance to Ag+ than its methicillin-susceptible
counterpart. Similarly, VREF required twice the dose of AgSD than the vancomycin-
susceptible strain. The phenomenon that resistant bacteria selected by exposure to one
antimicrobial frequently demonstrate resistance to other agents has been documented
repeatedly.40–42 For instance, an AgSD-resistant strain of Enterbacter cloacae isolated from
a burn wound unit also exhibited a resistance to kanamycin and carbenicillin not expressed
by AgSD-susceptible strains.43
Synergistic activity of AgSD and PROLI/NO in combination
Measurement of the bactericidal endpoint over a short treatment duration (2 h) focused the
definition of synergy in these experiments to short-term antimicrobial activity, as would be
required for most topical applications of these drug combinations in vivo. Using the
checkerboard technique, combinations of AgSD and PROLI/NO were screened against E.
coli, VSEF, VREF, P. mirabilis, P. aeruginosa, MSSA, MRSA and S. epidermidis.
Bactericidal synergism (FBC120 < 0.5) was evident for 4 out of 9 species tested. For one
bacterial species, MRSA, the therapeutic combination was highly synergistic (FBC120 <
0.25). While Gram-positive bacteria were least susceptible to both AgSD and PROLI/NO as
individual antimicrobial agents, the combination of AgSD and PROLI/NO was in fact
synergistic against these same species, with the exception of S. epidermidis. For example,
MRSA and both E. faecalis strains demonstrated high tolerance to each agent individually,
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but suffered the highest degree of susceptibility to the combination of AgSD and PROLI/
NO, requiring only 6.25 – 12.5% of either agent in combination compared to the
concentrations required for either of the agents alone. The MSSA strain also exhibited a high
degree of susceptibility to this combination, although MRSA was affected to a greater
degree. Of interest, P. aeruginosa was the most susceptible to AgSD alone, but synergy was
not observed from the combination of AgSD and PROLI/NO.
Table 2 indicates the percent of each individual agent needed to elicit the greatest degree of
synergy in combination. For the two most synergistic combinations (in Table 2, first two
species listed), the dose of PROLI/NO was reduced to 6.25% values when combined with
only 12.5% of the dose of AgSD. The much smaller percentage of PROLI/NO required for
combined efficacy indicates the importance of PROLI/NO’s role in catalyzing the
synergistic mechanism of action. Again using the checkerboard assay, the impact of varying
the sequence of addition and spacing between agents was tested (Table 3). PROLI/NO (6 g
L−1) and AgSD (0.200 g L−1) were added either simultaneously or at intervals of 15, 30, and
45 min using S. aureus as a test organism. The potential mechanistic implications of these
studies are discussed below.
Discussion
Bactericidal efficacy of PROLI/NO and AgSD
To understand the synergism observed in this study, it is first necessary to parse out the
mechanisms of AgSD and PROLI/NO action. The various roles of NO in killing bacteria
have been reviewed previously.10, 14, 17, 44 As an indiscriminate and short-lived reactant,
the target sites available in the immediate vicinity of NO (i.e., thiols, amines, transition-
metals, small molecules) play a key role in determining the type of antimicrobial action
rendered. The NO donor used in our study (PROLI/NO) releases NO rapidly upon exposure
to aqueous solution (t1/2 = 37 s, Figure 2),35, 45 where NO and its reactive intermediates
likely modify biomolecules on the exterior of bacteria, particularly membrane-bound
proteins and lipids. Reaction with O2− forms ONOO−, a strong oxidant that can degrade
membranes through lipid peroxidation and oxidize nearby proteins, compromising cellular
integrity. Additionally, NO is a lipophilic, uncharged, diatomic molecule that readily
diffuses across lipid membranes where it may react with intercellular proteins and DNA,
disrupting crucial cellular processes.. Thus, NO is both an extra- and intra-cellular threat to
bacteria.
Despite its broad application for treating chronic and burn wounds topically, AgSD’s
mechanism(s) of action remains uncertain. In aqueous media, AgSD gradually dissociates
into Ag+ and SD. Ionic silver reacts directly with thiol-containing amino acids.46
Mechanistic studies have shown that treatment with Ag+ affects DNA replication and
cellular respiration, among other functions.1–6 A member of the sulfonamide family of
semisynthetic antibacterial agents, SD is a biocide in its own right that can interfere with
folate synthesis by competitively binding the enzyme dihydropteroate synthase within the
cytoplasm of bacteria.47 This process is specifically detrimental to bacteria, as higher
organisms obtain this metabolite through dietary ingestion. At physiological pH ~7 SD is
negatively charged (pKa = 6.48)48 and less likely to diffuse across biological membranes to
access its intracellular target.47 Despite the potential antimicrobial activity of SD, it is
generally believed that Ag+ serves as the primary biocide upon AgSD dissociation, at least
for topical applications.49 This phenomenon was verified in our experiments by showing
that treatment with SD alone at concentrations equivalent to the MBC of AgSD did not
affect the viability of any of the organisms studied (Figure 1).
Deupree et al. Page 6













As evidenced by the ineffectiveness of SD, the ability of a biocide to access target sites is
imperative for antimicrobial efficacy. The outer membrane characteristic of Gram-negative
species acts as a particularly efficient permeability barrier, conferring intrinsic resistance to
host defense mechanisms, bile salts and digestive enzymes, and many biocides that are
effective against other types of bacteria.50 In the absence of differences in specificity, Gram-
negative bacteria frequently exhibit improved tolerance to agents that function
intracellularly compared to Gram-positive species.51 Hence, the greater efficacy of Ag+ and
NO (individually) observed against Gram-negative species may indicate that important
targets of these biocides reside on the exterior of the bacteria where the rate of passive
diffusion is less important. When considering the reactivity of Ag+, NO, and NO-derived
by-products, this is not entirely surprising. Empirical evidence drawn from morphological
observation supports this hypothesis. For example, electron micrographs of AgSD-treated P.
aeruginosa and Enterobacter cloacae have indicated altered cell wall morphology, while
resistant species did not show any changes.43, 52
Proposed mechanisms for the synergistic action of PROLI/NO and AgSD
Our control experiments clearly indicate that Ag+ and NO are the bactericidal agents
eliciting synergy. Two possible cooperative mechanisms seem plausible based on the
cumulative knowledge of Ag+ and NO activity, neither of which are mutually exclusive.
Agents that act by disrupting the structure of the lipid bilayer or otherwise compromising the
cell wall, independent of the level of individual bactericidal activity, should in principle
work synergistically when combined with a second agent whose activity is frustrated by low
levels of permeability. We have previously reported that NO is a potent membrane
degradation agent, damaging the bacterial membrane of gram-negative species.
Pseudomonas aeruginosa treated with NO were imaged with atomic force microscopy,
revealing widespread structural deformation and collapse of the bacterial membrane.45
These results were further corroborated by the observed penetration of propidium iodide, a
fluorescent dye that will only penetrate compromised cell membranes, upon exposure of P.
aeruginosa to NO.24 Synergistic mechanisms between cell wall- and cytoplasm-active
agents have been repeatedly demonstrated (e.g., the improved permeability of streptomycin
into E. faecalis in concert with cell wall-active agents such as penicillin and vancomycin),53,
54 and a similar phenomenon has been shown against other Gram-negative and -positive
species.34 We hypothesize that such synergism may occur if cell wall or membrane damage
elicited by Ag+ and, particularly, NO significantly increases the permeability of the bacteria
cell wall. Both of the antimicrobial agents evaluated in our study have intracellular activity
that would be expected to be enhanced by a faster rate of entry into the bacteria.
Furthermore, increased permeability of the lipid membrane would improve intracellular
access for anionic SD compounds.
Among other bactericidal mechanisms, Ag+ has been implicated in disruption of cellular
respiration. The uncoupling of the respiratory chain initially stimulates respiration as
bacteria attempt to regenerate the declining proton gradient across the membrane. Holt and
Bard showed that AgNO3 inhibited the respiratory chain by preventing the transport of
protons outside of the cell.6 One important implication of their study was the probable
accumulation of reactive oxygen species such as O2− and OH− at the membrane. The
bactericidal efficacy of NO would increase with the number of reactive by-products
produced (i.e., peroxynitrite).
The underlying synergistic mechanism may be indirectly probed by altering the sequence of
addition. If decoupling of cellular respiration plays an important role in the synergistic
mechanism, then the action of Ag+ must precede that of the highly reactive NO produced
from rapidly decomposing PROLI/NO unless increased cellular permeability is the major
contributing factor to the synergistic activity. In the latter case, the PROLI/NO likely elicits
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the degradation of membrane lipids prior to the subsequent contribution from increased
intracellular access of both Ag+ and NO. A series of bactericidal assays were thus performed
varying both the order and time of addition for each bactericidal agent (Table 3). The
addition of PROLI/NO prior to AgSD within a 15 min window and AgSD prior to PROLI/
NO within a 30 min window resulted in the greatest synergistic effect, suggesting that the
order of addition is not important within a narrow time period. Antimicrobial activity was
diminished when AgSD was added >30 min prior to PROLI/NO, perhaps due to reduced
potency of the AgSD in solution before any action on the cell walls by PROLIN/NO).
Similarly, antimicrobial efficacy was reduced when PROLI/NO was added >15 min prior to
AgSD, likely due to the short half-life of NO at physiological pH (~40 s). We hypothesize
that at additional periods beyond 15 min for PROLI/NO and 30 min for AgSD, either cell
division may result in new, non-damaged cells, or cell wall repair occurs despite the short-
lived presence of sub-bactericidal doses of NO.55 Any new or repaired cells would then be
unaffected by the addition of sub-bactericidal doses of AgSD, allowing normal proliferation
to occur.
To evaluate the potential effect of increased SD permeability, S. aureus bacteria were treated
with a range of SD concentrations in combination with doses of PROLI/NO at one half and
one quarter of the respective bactericidal levels. No enhanced activity was observed for S.
aureus, indicating that SD is not involved in the primary synergistic mechanism. Even the
lowest concentration of SD evaluated (0.105 g L−1) was almost three-fold greater than the
equivalent concentration of AgSD required for maximum cooperativity against P.
aeruginosa (0.005 g L−1) with a 12 g L−1 dose of PROLI/NO. These results indicated that
combination treatment with NO and SD was not particularly effective against S. aureus over
a 2 h time frame, although some enhanced effect may be expected to occur over longer
periods as endogenous folate reserves are depleted and cellular activity decreases due to
starvation. The primary mechanism of the acute synergy observed at 2 h involves both NO
and Ag+, and the evidence revealed in this study indicates that increased intracellular
concentrations of these two agents following membrane damage may play a significant role
in the observed synergistic activity.
Conclusions
The combination of AgSD and PROLI/NO is synergistic across a wide range of Gram-
positive bacteria, including antibiotic-resistant ‘super bugs’. By varying the interval of
addition of AgSD and PROLI/NO, we demonstrated that the duration between dosing of
individual agents is important in eliciting maximum synergistic activity. When the
concentration of AgSD or PROLI/NO is sub-bactericidal, the delay in the addition of the
second agent should not exceed some threshold time limit, presumably as the bacteria are
capable of repairing the membrane damage or dividing to form healthy cells, even while
under stress.
When AgSD and PROLI/NO were evaluated against bacteria individually, Gram-negative
bacteria were the most susceptible to treatment, with as little as 0.020 g L−1 AgSD and 1 g
L−1 PROLI/NO required for a 3-log reduction in viability of P. aeruginosa and E. coli
(JM109), respectively. Gram-positive bacteria were the most susceptible to the cooperative
effect of the combination of AgSD and PROLI/NO. In the case of MRSA, only 12.5% of the
AgSD and 6.25% of the PROLI/NO was required to be bactericidal in combination
compared to the concentrations needed when used individually. The evidence presented
herein provides an impetus to further investigate the clinical uses of NO in combination with
AgSD and other antibiotics. Possessing the ability to rapidly eradicate a wide range of
bacterial species, such combinations may be particularly useful in topical wound treatments
due to the potential for treating polymicrobial and antibiotic-resistant infections while
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reducing selection for resistant species. Further mechanistic studies aimed at elucidating the
synergistic action of AgSD and NO would provide a strong foundation for developing and
improving additional combination therapies. In addition, studies examining both the
cytotoxicity and in vivo efficacy of the therapy are necessary prior to clinical application.
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Change in concentration of S. aureus and P. aeruginosa after 2 h of exposure to proline and
sulfadiazine at molar equivalents to the MBC of PROLI/NO and AgSD, respectively, in
TSB at 37 °C.
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Instantaneous NO release from 0.133 mg PROLI/NO added to PBS (pH 7.4) at 37 °C.
Deupree et al. Page 13

























Deupree et al. Page 14
TABLE 1
Minimum bactericidal concentrations of PROLI/NO and AGSD required for a 3-log reduction in viable
bacteria after 120 min of exposure.
Species Gram class MBC120 AgSD (g L−1) MBC120 PROLI/NO (g L−1)
E. faecalis + 2.00 72
VREF + 4.00 60
S. aureus + 0.600 48
S. epidermidis + 0.100 36
MRSA + 3.20 36
E. coli (JM109) − 0.050 1
E. coli (O157:H7) − 0.200 24
P. aeruginosa − 0.020 8
P. mirabilis − 0.100 12
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TABLE 3
Change in S. aureus viability at 120 min after exposure to 6 g L−1 PROLI/NO (PNO), 0.200 g L−1 AgSD,
varying the sequence and interval between additions. Addition interval denotes time period between the
addition of the first and second agent.
Agent 1 Addition interval (min) Agent 2 Bacterial viability change (log change)
AgSD 45 PNO −1.61
AgSD 30 PNO −2.35
AgSD 15 PNO −2.64
PNO 45 AgSD −0.51
PNO 30 AgSD −0.37
PNO 15 AgSD −2.55
AgSD 0 PNO −2.46
PNO N/A N/A +0.11
AgSD N/A N/A −1.66
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